Comparative effectiveness of TNF inhibitors and tocilizumab with and without conventional synthetic disease-modifying antirheumatic drugs in a pan-European observational cohort of bio-naïve patients with rheumatoid arthritis

Lauper, Kim; Mongin, Denis; Iannone, Florenzo; Kristianslund, Eirik K; Kvien, Tore K; Nordström, Dan C; Pavelka, Karel; Pombo-Suarez, Manuel; Rotar, Ziga; Santos, Maria J; Codreanu, Catalin; Lukina, Galina; Gale, Sara L; John, Markus; Luder, Yves; Courvoisier, Delphine; Gabay, Cem

doi:10.1016/j.semarthrit.2019.06.020

Scientific article

Open access

English

Comparative effectiveness of TNF inhibitors and tocilizumab with and without conventional synthetic disease-modifying antirheumatic drugs in a pan-European observational cohort of bio-naïve patients with rheumatoid arthritis

ContributorsLauper, Kim

; Mongin, Denis

; Iannone, Florenzo; Kristianslund, Eirik K; Kvien, Tore K; Nordström, Dan C; Pavelka, Karel; Pombo-Suarez, Manuel; Rotar, Ziga; Santos, Maria J; Codreanu, Catalin; Lukina, Galina; Gale, Sara L; John, Markus; Luder, Yves; Courvoisier, Delphine; Gabay, Cem

Published inSeminars in Arthritis and Rheumatism

Publication date2019

Abstract

To compare treatment effectiveness in rheumatoid arthritis (RA) patients naïve to biological disease-modifying antirheumatic drugs (bDMARDs) treated with tocilizumab (TCZ) or TNF-inhibitor (TNFi) with (-combo) or without (-mono) conventional synthetic DMARDs (csDMARDs).

Keywords

Biological therapies
DMARDs
Monotherapy
Rheumatoid arthritis
TNF inhibitors
Tocilizumab

Affiliation

Faculté de médecine / Section de médecine clinique / Département de médecine

Research group

Citation (ISO format)

LAUPER, Kim et al. Comparative effectiveness of TNF inhibitors and tocilizumab with and without conventional synthetic disease-modifying antirheumatic drugs in a pan-European observational cohort of bio-naïve patients with rheumatoid arthritis. In: Seminars in Arthritis and Rheumatism, 2019. doi: 10.1016/j.semarthrit.2019.06.020